Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25863038)

  • 1. SKOV-3 and Me45 cell response to cisplatin-based chemotherapy: an in vitro study.
    Gonera A; Wawryka J; Sobkowicz A; Biezunska-Kusiak K; Dubinska-Magiera M; Krajewski A; Choromanska A
    Folia Biol (Praha); 2014; 60(5):213-9. PubMed ID: 25863038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
    Wang W; Liu G; Zheng J
    Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
    Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
    Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
    Cheng G; Li Y; Tian F
    Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
    Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of GST-π and polβ genes in chemoresistance of esophageal carcinoma cells.
    Tang Y; Xuan XY; Li M; Dong ZM
    Asian Pac J Cancer Prev; 2013; 14(12):7375-9. PubMed ID: 24460306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.
    Yang M; Li Y; Shen X; Ruan Y; Lu Y; Jin X; Song P; Guo Y; Zhang X; Qu H; Shao Y; Quan C
    J Exp Clin Cancer Res; 2017 Nov; 36(1):157. PubMed ID: 29116019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
    J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
    Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance.
    Yamamoto K; Okamoto A; Isonishi S; Ochiai K; Ohtake Y
    Cancer Lett; 2001 Jul; 168(2):173-81. PubMed ID: 11403922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
    Jin Z; Guan T; Li S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):218-20. PubMed ID: 12048682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of genes of glutathione transferase isoforms GSTP1-1, GSTA4-4, and GSTK1-1 in tumor cells during the formation of drug resistance to cisplatin.
    Kalinina EV; Berozov TT; Shtil AA; Chernov NN; Glasunova VA; Novichkova MD; Nurmuradov NK
    Bull Exp Biol Med; 2012 Nov; 154(1):64-7. PubMed ID: 23330092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect and mechanism of peroxisome proliferator-activated receptor-γ on the drug resistance of the U-87 MG/CDDP human malignant glioma cell line.
    Han S; Lv X; Wang Y; Gong H; Zhang C; Tong A; Zhang B; Yao H
    Mol Med Rep; 2015 Aug; 12(2):2239-46. PubMed ID: 25891367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy.
    Cheng X; Kigawa J; Minagawa Y; Kanamori Y; Itamochi H; Okada M; Terakawa N
    Cancer; 1997 Feb; 79(3):521-7. PubMed ID: 9028363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
    Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
    Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.